{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:38Z","timestamp":1792025198412,"version":"4.4.0"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"DOI":"10.1038\/s41584-026-01441-y","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:02:49Z","timestamp":1791975769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging therapies for knee osteoarthritis"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-701X","authenticated-orcid":false,"given":"Alice","family":"Courties","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-4680","authenticated-orcid":false,"given":"Tobias","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-5665","authenticated-orcid":false,"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8252-7815","authenticated-orcid":false,"given":"Francis","family":"Berenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1441_CR1","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","volume":"5","author":"GBD 2021 Osteoarthritis Collaborators","year":"2023","unstructured":"GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 5, e508\u2013e522 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1441_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100587","volume":"29\u201330","author":"A Cui","year":"2020","unstructured":"Cui, A. et al. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine 29\u201330, 100587 (2020).","journal-title":"EClinicalMedicine"},{"key":"1441_CR3","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.joca.2016.03.012","volume":"24","author":"JH Salmon","year":"2016","unstructured":"Salmon, J. H. et al. Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthr. Cartil. 24, 1500\u20131508 (2016).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/jgs.16159","volume":"68","author":"P Siviero","year":"2020","unstructured":"Siviero, P. et al. Association between osteoarthritis and social isolation: data From the EPOSA study. J. Am. Geriatr. Soc. 68, 87\u201395 (2020).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1441_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep39672","volume":"6","author":"H Wang","year":"2016","unstructured":"Wang, H., Bai, J., He, B., Hu, X. & Liu, D. Osteoarthritis and the risk of cardiovascular disease: a meta-analysis of observational studies. Sci. Rep. 6, 39672 (2016).","journal-title":"Sci. Rep."},{"key":"1441_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29581-1","volume":"13","author":"D Park","year":"2023","unstructured":"Park, D. et al. Association between knee osteoarthritis and the risk of cardiovascular disease and the synergistic adverse effects of lack of exercise. Sci. Rep. 13, 2777 (2023).","journal-title":"Sci. Rep."},{"key":"1441_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.semarthrit.2016.04.002","volume":"46","author":"N Veronese","year":"2016","unstructured":"Veronese, N. et al. Osteoarthritis and mortality: a prospective cohort study and systematic review with meta-analysis. Semin. Arthritis Rheum. 46, 160\u2013167 (2016).","journal-title":"Semin. Arthritis Rheum."},{"key":"1441_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d1165","volume":"342","author":"E N\u00fcesch","year":"2011","unstructured":"N\u00fcesch, E. et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 342, d1165 (2011).","journal-title":"BMJ"},{"key":"1441_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/BOR.0000000000000373","volume":"29","author":"A Courties","year":"2017","unstructured":"Courties, A., Sellam, J. & Berenbaum, F. Metabolic syndrome-associated osteoarthritis. Curr. Opin. Rheumatol. 29, 214\u2013222 (2017).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1441_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-026-08277-w","volume":"24","author":"J Luo","year":"2026","unstructured":"Luo, J. et al. Systemic implications of osteoarthritis: from local degeneration to systemic metabolic dysregulation. J. Transl. Med. 24, 808 (2026).","journal-title":"J. Transl. Med."},{"key":"1441_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2019.06.011","author":"RR Bannuru","year":"2019","unstructured":"Bannuru, R. R. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr. Cartil. https:\/\/doi.org\/10.1016\/j.joca.2019.06.011 (2019).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/art.41142","volume":"72","author":"SL Kolasinski","year":"2020","unstructured":"Kolasinski, S. L. et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 72, 220\u2013233 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.joca.2019.01.005","volume":"27","author":"JB Thorlund","year":"2019","unstructured":"Thorlund, J. B., Turkiewicz, A., Prieto-Alhambra, D. & Englund, M. Opioid use in knee or hip osteoarthritis: a region-wide population-based cohort study. Osteoarthr. Cartil. 27, 871\u2013877 (2019).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration.","year":"2013","unstructured":"Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769\u2013779 (2013).","journal-title":"Lancet"},{"key":"1441_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2321","volume":"375","author":"BR da Costa","year":"2021","unstructured":"da Costa, B. R. et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ 375, n2321 (2021).","journal-title":"BMJ"},{"key":"1441_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000435","volume":"2","author":"AD Beswick","year":"2012","unstructured":"Beswick, A. D., Wylde, V., Gooberman-Hill, R., Blom, A. & Dieppe, P. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. BMJ Open 2, e000435 (2012).","journal-title":"BMJ Open"},{"key":"1441_CR17","unstructured":"Endoprothesenregister Deutsche. EPRD Annual Report 2025 https:\/\/www.eprd.de\/en\/about-the-eprd\/news\/article\/eprd-annual-report-2025 (EPRD, 2026)."},{"key":"1441_CR18","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","volume":"393","author":"DJ Hunter","year":"2019","unstructured":"Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745\u20131759 (2019).","journal-title":"Lancet"},{"key":"1441_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMcp1903768","volume":"384","author":"L Sharma","year":"2021","unstructured":"Sharma, L. Osteoarthritis of the knee. N. Engl. J. Med. 384, 51\u201359 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1441_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-9-116","volume":"9","author":"J Bedson","year":"2008","unstructured":"Bedson, J. & Croft, P. R. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet. Disord. 9, 116 (2008).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1441_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.7326\/M19-0675","volume":"172","author":"PG Conaghan","year":"2020","unstructured":"Conaghan, P. G. et al. Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized controlled trial. Ann. Intern. Med. 172, 86\u201395 (2020).","journal-title":"Ann. Intern. Med."},{"key":"1441_CR22","unstructured":"U.S. Food and Drug Administration. Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and Biological Products for Treatment: Guidance for Industry (FDA, 2018)."},{"key":"1441_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2020.100059","volume":"2","author":"JN Katz","year":"2020","unstructured":"Katz, J. N. et al. Disease modification in osteoarthritis; pathways to drug approval. Osteoarthr. Cartil. Open 2, 100059 (2020).","journal-title":"Osteoarthr. Cartil. Open"},{"key":"1441_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41584-025-01280-3","volume":"21","author":"V Batchelor","year":"2025","unstructured":"Batchelor, V., Perry, T. A., Cader, M. Z. & Vincent, T. L. Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain. Nat. Rev. Rheumatol. 21, 526\u2013545 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrrheum.2013.138","volume":"9","author":"A-M Malfait","year":"2013","unstructured":"Malfait, A.-M. & Schnitzer, T. J. Towards a mechanism-based approach to pain management in osteoarthritis. Nat. Rev. Rheumatol. 9, 654\u2013664 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR26","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1097\/j.pain.0000000000001923","volume":"161","author":"TL Vincent","year":"2020","unstructured":"Vincent, T. L. Peripheral pain mechanisms in osteoarthritis. Pain 161, S138\u2013S146 (2020).","journal-title":"Pain"},{"key":"1441_CR27","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/ard.2006.063354","volume":"66","author":"S Suri","year":"2007","unstructured":"Suri, S. et al. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Ann. Rheum. Dis. 66, 1423\u20131428 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR28","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.joca.2020.05.010","volume":"28","author":"K Aso","year":"2020","unstructured":"Aso, K. et al. Contribution of nerves within osteochondral channels to osteoarthritis knee pain in humans and rats. Osteoarthr. Cartil. 28, 1245\u20131254 (2020).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR29","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/art.41674","volume":"73","author":"MC Hochberg","year":"2021","unstructured":"Hochberg, M. C. et al. Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis Rheumatol. 73, 1167\u20131177 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR30","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","volume":"363","author":"NE Lane","year":"2010","unstructured":"Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521\u20131531 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1441_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","volume":"79","author":"F Berenbaum","year":"2020","unstructured":"Berenbaum, F. et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann. Rheum. Dis. 79, 800\u2013810 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR32","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.41012","volume":"71","author":"P Dakin","year":"2019","unstructured":"Dakin, P. et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb\/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 71, 1824\u20131834 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-006436","volume":"12","author":"SJ DiMartino","year":"2026","unstructured":"DiMartino, S. J. et al. A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hip. RMD Open 12, e006436 (2026).","journal-title":"RMD Open"},{"key":"1441_CR34","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1080\/03007995.2019.1653068","volume":"35","author":"KM Kelly","year":"2019","unstructured":"Kelly, K. M. et al. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies. Curr. Med. Res. Opin. 35, 2117\u20132127 (2019).","journal-title":"Curr. Med. Res. Opin."},{"key":"1441_CR35","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.joca.2019.07.013","volume":"27","author":"DA Walsh","year":"2019","unstructured":"Walsh, D. A. & Neogi, T. A tale of two TrkA inhibitor trials: same target, divergent results. Osteoarthr. Cartil. 27, 1575\u20131577 (2019).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s12035-014-8706-9","volume":"50","author":"M Richner","year":"2014","unstructured":"Richner, M. et al. Peripheral nerve injury modulates neurotrophin signaling in the peripheral and central nervous system. Mol. Neurobiol. 50, 945\u2013970 (2014).","journal-title":"Mol. Neurobiol."},{"key":"1441_CR37","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/S0140-6736(26)00131-5","volume":"407","author":"PG Conaghan","year":"2026","unstructured":"Conaghan, P. G. et al. Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 407, 1237\u20131248 (2026).","journal-title":"Lancet"},{"key":"1441_CR38","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.joca.2023.08.010","volume":"31","author":"JA Carrino","year":"2023","unstructured":"Carrino, J. A. et al. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab. Osteoarthr. Cartil. 31, 1612\u20131626 (2023).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41584-024-01146-0","volume":"20","author":"R Zhou","year":"2024","unstructured":"Zhou, R., Fu, W., Vasylyev, D., Waxman, S. G. & Liu, C.-J. Ion channels in osteoarthritis: emerging roles and potential targets. Nat. Rev. Rheumatol. 20, 545\u2013564 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nrd2280","volume":"6","author":"A Szallasi","year":"2007","unstructured":"Szallasi, A., Cortright, D. N., Blum, C. A. & Eid, S. R. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 6, 357\u2013372 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1441_CR41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40263-026-01272-1","volume":"40","author":"EH Tsai","year":"2026","unstructured":"Tsai, E. H. & Gan, T. J. TRPV1 receptor modulators: emerging therapies for neuropathic, osteoarthritic, and perioperative pain. CNS Drugs 40, 523\u2013534 (2026).","journal-title":"CNS Drugs"},{"key":"1441_CR42","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/art.40894","volume":"71","author":"RM Stevens","year":"2019","unstructured":"Stevens, R. M. et al. Randomized, double-blind, placebo-controlled trial of intraarticular trans-capsaicin for pain associated with osteoarthritis of the knee. Arthritis Rheumatol. 71, 1524\u20131533 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR43","doi-asserted-by":"crossref","DOI":"10.1002\/art.42535","volume":"75","author":"J Connolly","year":"2023","unstructured":"Connolly, J., Campbell, J., Stevens, R. & Newman, C. Combined datasets for CNTX-4975 osteoarthritis knee pain (OAKP) phase 3 trials (OAKP 301 and 304) to assess overall efficacy and safety of an intra-articular injection (IAI) of CNTX-4975-05 (CNTX) in subjects with chronic, moderate-to-severe osteoarthritis knee pain (MSOAKP) [abstract]. Arthritis Rheumatol. 75, 1977 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR44","volume":"76","author":"T Ostenfeld","year":"2024","unstructured":"Ostenfeld, T., Ivanicius, S., Stancik, R. & Conaghan, P. An evaluation of the efficacy, pharmacokinetics and safety, of the transient receptor potential vanilloid 1 (TRPV1) agonist RTX-GRT7039 \u2014 a placebo-controlled study in patients with osteoarthritis knee pain [abstract]. Arthritis Rheumatol. 76, 1211 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR45","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/17581869.2025.2535271","volume":"15","author":"MJ Iadarola","year":"2025","unstructured":"Iadarola, M. J., Sapio, M. R., Nahama, A. & Mannes, A. J. Intraarticular resiniferatoxin, a potent TRPV1 agonist, for treatment of osteoarthritic pain. Pain Manag. 15, 659\u2013670 (2025).","journal-title":"Pain Manag."},{"key":"1441_CR46","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.tins.2007.08.004","volume":"30","author":"SD Dib-Hajj","year":"2007","unstructured":"Dib-Hajj, S. D., Cummins, T. R., Black, J. A. & Waxman, S. G. From genes to pain: Nav1.7 and human pain disorders. Trends Neurosci. 30, 555\u2013563 (2007).","journal-title":"Trends Neurosci."},{"key":"1441_CR47","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1172\/JCI33297","volume":"117","author":"JPH Drenth","year":"2007","unstructured":"Drenth, J. P. H. & Waxman, S. G. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J. Clin. Invest. 117, 3603\u20133609 (2007).","journal-title":"J. Clin. Invest."},{"key":"1441_CR48","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41586-023-06888-7","volume":"625","author":"W Fu","year":"2024","unstructured":"Fu, W. et al. Nav1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis. Nature 625, 557\u2013565 (2024).","journal-title":"Nature"},{"key":"1441_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-physiol-030212-183811","volume":"75","author":"DM Bautista","year":"2013","unstructured":"Bautista, D. M., Pellegrino, M. & Tsunozaki, M. TRPA1: a gatekeeper for inflammation. Annu. Rev. Physiol. 75, 181\u2013200 (2013).","journal-title":"Annu. Rev. Physiol."},{"key":"1441_CR50","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1097\/j.pain.0000000000003487","volume":"166","author":"MM Mellado Lagarde","year":"2024","unstructured":"Mellado Lagarde, M. M. et al. Clinical proof-of-concept results with a novel TRPA1 antagonist (LY3526318) in 3 chronic pain states. Pain 166, 1497\u20131518 (2024).","journal-title":"Pain"},{"key":"1441_CR51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neuropharm.2017.06.015","volume":"124","author":"SG Woodhams","year":"2017","unstructured":"Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G. & Neugebauer, V. The cannabinoid system and pain. Neuropharmacology 124, 105\u2013120 (2017).","journal-title":"Neuropharmacology"},{"key":"1441_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100777","volume":"35","author":"S Pramhas","year":"2023","unstructured":"Pramhas, S. et al. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. Lancet Reg. Health Eur. 35, 100777 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"1441_CR53","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-bioeng-081514-123305","volume":"18","author":"S Jahn","year":"2016","unstructured":"Jahn, S., Seror, J. & Klein, J. Lubrication of articular cartilage. Annu. Rev. Biomed. Eng. 18, 235\u2013258 (2016).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"1441_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000071","volume":"1","author":"P Richette","year":"2015","unstructured":"Richette, P. et al. Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias. RMD Open 1, e000071 (2015).","journal-title":"RMD Open"},{"key":"1441_CR55","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.joca.2025.04.006","volume":"33","author":"TJ Schnitzer","year":"2025","unstructured":"Schnitzer, T. J. et al. Intra-articular MM-II for the treatment of knee osteoarthritis pain: efficacy and safety results from a 26-week, phase 2b, placebo-controlled, double-blind, randomized dose-ranging trial. Osteoarthr. Cartil. 33, 897\u2013906 (2025).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.cger.2021.11.013","volume":"38","author":"MJ Wood","year":"2022","unstructured":"Wood, M. J., Miller, R. E. & Malfait, A.-M. The genesis of pain in osteoarthritis: inflammation as a mediator of osteoarthritis pain. Clin. Geriatr. Med. 38, 221\u2013238 (2022).","journal-title":"Clin. Geriatr. Med."},{"key":"1441_CR57","doi-asserted-by":"publisher","first-page":"666","DOI":"10.2106\/JBJS.17.00154","volume":"100","author":"PG Conaghan","year":"2018","unstructured":"Conaghan, P. G. et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. J. Bone Jt. Surg. Am. 100, 666\u2013677 (2018).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"1441_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02739-4","volume":"24","author":"DJ Hunter","year":"2022","unstructured":"Hunter, D. J. et al. TLC599 in patients with osteoarthritis of the knee: a phase IIa, randomized, placebo-controlled, dose-finding study. Arthritis Res. Ther. 24, 52 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"1441_CR59","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/j.joca.2025.02.171","volume":"33","author":"Z Zhu","year":"2025","unstructured":"Zhu, Z. et al. Extended and controlled release liposomal formulated dexamethasone (TLC599) for chronic knee osteoarthritis pain (EXCELLENCE): a phase 3, randomized, placebo-controlled clinical trial [abstract 166]. Osteoarthr. Cartil. 33, S125\u2013S126 (2025).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR60","doi-asserted-by":"publisher","first-page":"e860","DOI":"10.1016\/S2665-9913(24)00223-6","volume":"6","author":"A Malone","year":"2024","unstructured":"Malone, A. et al. Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial. Lancet Rheumatol. 6, e860\u2013e870 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1441_CR61","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1001\/jama.2017.5283","volume":"317","author":"TE McAlindon","year":"2017","unstructured":"McAlindon, T. E. et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA 317, 1967\u20131975 (2017).","journal-title":"JAMA"},{"key":"1441_CR62","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/art.42118","volume":"74","author":"A Latourte","year":"2022","unstructured":"Latourte, A. et al. Do glucocorticoid injections increase the risk of knee osteoarthritis progression over 5\u2009years? Arthritis Rheumatol. 74, 1343\u20131351 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR63","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.joca.2019.01.007","volume":"27","author":"C Zeng","year":"2019","unstructured":"Zeng, C. et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthr. Cartil. 27, 855\u2013862 (2019).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR64","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.joca.2024.02.948","volume":"32","author":"AR Bihlet","year":"2024","unstructured":"Bihlet, A. R. et al. The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: a double-blind, randomized, placebo-controlled, clinical trial. Osteoarthr. Cartil. 32, 952\u2013962 (2024).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR65","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.7326\/M24-0303","volume":"177","author":"SR Kingsbury","year":"2024","unstructured":"Kingsbury, S. R. et al. Pain reduction with oral methotrexate in knee osteoarthritis: a randomized, placebo-controlled clinical trial. Ann. Intern. Med. 177, 1145\u20131156 (2024).","journal-title":"Ann. Intern. Med."},{"key":"1441_CR66","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/jamainternmed.2025.1359","volume":"185","author":"Z Zhu","year":"2025","unstructured":"Zhu, Z. et al. Low-dose methotrexate for the treatment of inflammatory knee osteoarthritis: a randomized clinical trial. JAMA Intern. Med. 185, 808\u2013816 (2025).","journal-title":"JAMA Intern. Med."},{"key":"1441_CR67","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.joca.2026.07.002","volume":"34","author":"J Liang","year":"2026","unstructured":"Liang, J. et al. Systemic biomarkers of treatment response to methotrexate in people with painful knee osteoarthritis: a biological substudy of the PROMOTE randomised controlled clinical trial. Osteoarthr. Cartil. 34, 1539\u20131549 https:\/\/doi.org\/10.1016\/j.joca.2026.07.002 (2026).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR68","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.joca.2015.05.016","volume":"23","author":"A Courties","year":"2015","unstructured":"Courties, A., Gualillo, O., Berenbaum, F. & Sellam, J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthr. Cartil. 23, 1955\u20131965 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR69","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41584-024-01143-3","volume":"20","author":"M Binvignat","year":"2024","unstructured":"Binvignat, M., Sellam, J., Berenbaum, F. & Felson, D. T. The role of obesity and adipose tissue dysfunction in osteoarthritis pain. Nat. Rev. Rheumatol. 20, 565\u2013584 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR70","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.soard.2021.04.019","volume":"17","author":"EAF Heuts","year":"2021","unstructured":"Heuts, E. A. F., de Jong, L. D., Hazebroek, E. J., Wagener, M. & Somford, M. P. The influence of bariatric surgery on hip and knee joint pain: a systematic review. Surg. Obes. Relat. Dis. 17, 1637\u20131653 (2021).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"1441_CR71","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/ard.2006.065904","volume":"66","author":"R Christensen","year":"2007","unstructured":"Christensen, R., Bartels, E. M., Astrup, A. & Bliddal, H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 66, 433\u2013439 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR72","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41584-025-01302-0","volume":"21","author":"D Karacabeyli","year":"2025","unstructured":"Karacabeyli, D. & Lacaille, D. Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions. Nat. Rev. Rheumatol. 21, 671\u2013683 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR73","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal, H. et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N. Engl. J. Med. 391, 1573\u20131583 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1441_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt0548","volume":"388","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Osteoarthritis treatment via the GLP-1-mediated gut\u2013joint axis targets intestinal FXR signaling. Science 388, eadt0548 (2025).","journal-title":"Science"},{"key":"1441_CR75","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.cmet.2026.01.008","volume":"38","author":"H Qin","year":"2026","unstructured":"Qin, H. et al. Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism. Cell Metab. 38, 582\u2013597.e6 (2026).","journal-title":"Cell Metab."},{"key":"1441_CR76","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity \u2013 a phase 2 trial. N. Engl. J. Med. 389, 514\u2013526 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1441_CR77","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.7326\/ANNALS-24-03609","volume":"178","author":"DJ Betensky","year":"2025","unstructured":"Betensky, D. J. et al. The cost-effectiveness of semaglutide and tirzepatide for patients with knee osteoarthritis and obesity. Ann. Intern. Med. 178, 1549\u20131560 (2025).","journal-title":"Ann. Intern. Med."},{"key":"1441_CR78","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172","volume":"7","author":"D Do","year":"2024","unstructured":"Do, D. et al. GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes. JAMA Netw. Open 7, e2413172 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1441_CR79","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes. Metab. 24, 1553\u20131564 (2022).","journal-title":"Diabetes Obes. Metab."},{"key":"1441_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-026-01258-5","author":"A Ceriello","year":"2026","unstructured":"Ceriello, A. et al. Causes and consequences of discontinuation of GLP1RAs or tirzepatide. Nat. Rev. Endocrinol. https:\/\/doi.org\/10.1038\/s41574-026-01258-5 (2026).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1441_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jama.2024.6586","volume":"332","author":"C Conte","year":"2024","unstructured":"Conte, C., Hall, K. D. & Klein, S. Is weight loss-induced muscle mass loss clinically relevant? JAMA 332, 9\u201310 (2024).","journal-title":"JAMA"},{"key":"1441_CR82","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s13679-024-00571-2","volume":"13","author":"S Mirzai","year":"2024","unstructured":"Mirzai, S. et al. Sarcopenic obesity and cardiovascular disease: an overlooked but high-risk syndrome. Curr. Obes. Rep. 13, 532\u2013544 (2024).","journal-title":"Curr. Obes. Rep."},{"key":"1441_CR83","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.joca.2025.02.780","volume":"33","author":"M Almeida","year":"2025","unstructured":"Almeida, M. et al. Efficacy and safety of minimally invasive interventions targeting the genicular nerves for knee osteoarthritis: a meta-analysis. Osteoarthr. Cartil. 33, 535\u2013547 (2025).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR84","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.42384","volume":"75","author":"EM Shanahan","year":"2023","unstructured":"Shanahan, E. M. et al. Genicular nerve block for pain management in patients with knee osteoarthritis: a randomized placebo-controlled trial. Arthritis Rheumatol. 75, 201\u2013209 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-094576","volume":"15","author":"PRde Wit","year":"2025","unstructured":"Wit, P. R. de et al. Genicular nerve radiofrequency ablation, phenol neurolysis or conservative medical management in patients with knee osteoarthritis: protocol for the RADIOPHENOL randomised controlled multicentre trial with three parallel groups. BMJ Open 15, e094576 (2025).","journal-title":"BMJ Open"},{"key":"1441_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016377","volume":"7","author":"J Mata","year":"2017","unstructured":"Mata, J., Valent\u00ed, P., Hern\u00e1ndez, B., Mir, B. & Aguilar, J. L. Study protocol for a randomised controlled trial of ultrasound-guided pulsed radiofrequency of the genicular nerves in the treatment of patients with osteoarthritis knee pain. BMJ Open 7, e016377 (2017).","journal-title":"BMJ Open"},{"key":"1441_CR87","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.joca.2017.03.006","volume":"25","author":"R Radnovich","year":"2017","unstructured":"Radnovich, R. et al. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. Osteoarthr. Cartil. 25, 1247\u20131256 (2017).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR88","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jvir.2017.02.033","volume":"28","author":"Y Okuno","year":"2017","unstructured":"Okuno, Y., Korchi, A. M., Shinjo, T., Kato, S. & Kaneko, T. Midterm clinical outcomes and mr imaging changes after transcatheter arterial embolization as a treatment for mild to moderate radiographic knee osteoarthritis resistant to conservative treatment. J. Vasc. Interv. Radiol. 28, 995\u20131002 (2017).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"1441_CR89","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.243648","volume":"316","author":"FN Fleckenstein","year":"2025","unstructured":"Fleckenstein, F. N. et al. Genicular artery embolization for the treatment of symptomatic knee osteoarthritis. Radiology 316, e243648 (2025).","journal-title":"Radiology"},{"key":"1441_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-087047","volume":"14","author":"TA van Zadelhoff","year":"2024","unstructured":"van Zadelhoff, T. A. et al. Genicular artery embolisation versus sham embolisation for symptomatic osteoarthritis of the knee: a randomised controlled trial. BMJ Open 14, e087047 (2024).","journal-title":"BMJ Open"},{"key":"1441_CR91","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1302\/2633-1462.43.BJO-2022-0161.R2","volume":"4","author":"S Landers","year":"2023","unstructured":"Landers, S. et al. Genicular artery embolization for early-stage knee osteoarthritis: results from a triple-blind single-centre randomized controlled trial. Bone Jt. Open 4, 158\u2013167 (2023).","journal-title":"Bone Jt. Open"},{"key":"1441_CR92","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jvir.2021.09.019","volume":"33","author":"S Bagla","year":"2022","unstructured":"Bagla, S. et al. Multicenter randomized sham controlled study of genicular artery embolization for knee pain secondary to osteoarthritis. J. Vasc. Interv. Radiol. 33, 2\u201310.e2 (2022).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"1441_CR93","first-page":"97","volume":"123","author":"F Collettini","year":"2026","unstructured":"Collettini, F. et al. Transarterial embolization in osteoarthritis of the knee: mechanism of action and current results. Dtsch. Arztebl Int. 123, 97\u2013101 (2026).","journal-title":"Dtsch. Arztebl Int."},{"key":"1441_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14062106","volume":"14","author":"JM Brown","year":"2025","unstructured":"Brown, J. M., Vandeveer, Z. T., Cadoret, D., Morrison, J. J. & Jahangiri, Y. Genicular artery embolization: a technical review of anatomy, pathophysiology, current experiences, and future directions. J. Clin. Med. 14, 2106 (2025).","journal-title":"J. Clin. Med."},{"key":"1441_CR95","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrrheum.2010.159","volume":"6","author":"J Sellam","year":"2010","unstructured":"Sellam, J. & Berenbaum, F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat. Rev. Rheumatol. 6, 625\u2013635 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR96","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1136\/ard.2006.067470","volume":"66","author":"CL Hill","year":"2007","unstructured":"Hill, C. L. et al. Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann. Rheum. Dis. 66, 1599\u20131603 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR97","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1136\/ard.2009.121426","volume":"69","author":"K Baker","year":"2010","unstructured":"Baker, K. et al. Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann. Rheum. Dis. 69, 1779\u20131783 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR98","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.joca.2021.03.018","volume":"29","author":"AD Obotiba","year":"2021","unstructured":"Obotiba, A. D. et al. Synovitis and bone marrow lesions associate with symptoms and radiographic progression in hand osteoarthritis: a systematic review and meta-analysis of observational studies. Osteoarthr. Cartil. 29, 946\u2013955 (2021).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1560-9","volume":"20","author":"M-C Lee","year":"2018","unstructured":"Lee, M.-C. et al. CCL17 blockade as a therapy for osteoarthritis pain and disease. Arthritis Res. Ther. 20, 62 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"1441_CR100","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/ard-2023-225434","volume":"84","author":"JS Nijjar","year":"2025","unstructured":"Nijjar, J. S. et al. Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept study. Ann. Rheum. Dis. 84, 856\u2013865 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64710-6","volume":"16","author":"F Rannou","year":"2025","unstructured":"Rannou, F. et al. Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study. Nat. Commun. 16, 9767 (2025).","journal-title":"Nat. Commun."},{"key":"1441_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/ar3430","volume":"13","author":"SB Cohen","year":"2011","unstructured":"Cohen, S. B. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13, R125 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"1441_CR103","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/art.40840","volume":"71","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann, R. M. et al. A phase II trial of lutikizumab, an anti-interleukin-1\u03b1\/\u03b2 dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. Arthritis Rheumatol. 71, 1056\u20131069 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR104","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1441_CR105","doi-asserted-by":"publisher","first-page":"509","DOI":"10.7326\/M20-0527","volume":"173","author":"M Schieker","year":"2020","unstructured":"Schieker, M. et al. Effects of interleukin-1\u03b2 inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 173, 509\u2013515 (2020).","journal-title":"Ann. Intern. Med."},{"key":"1441_CR106","doi-asserted-by":"publisher","first-page":"737","DOI":"10.7326\/M23-0289","volume":"176","author":"MWJ Heijman","year":"2023","unstructured":"Heijman, M. W. J. et al. Association of low-dose colchicine with incidence of knee and hip replacements: exploratory analyses from a randomized, controlled, double-blind trial. Ann. Intern. Med. 176, 737\u2013742 (2023).","journal-title":"Ann. Intern. Med."},{"key":"1441_CR107","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13789","volume":"17","author":"E Gatlik","year":"2024","unstructured":"Gatlik, E. et al. First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor. Clin. Transl. Sci. 17, e13789 (2024).","journal-title":"Clin. Transl. Sci."},{"key":"1441_CR108","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0049-0172(99)80021-3","volume":"28","author":"P Ghosh","year":"1999","unstructured":"Ghosh, P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin. Arthritis Rheum. 28, 211\u2013267 (1999).","journal-title":"Semin. Arthritis Rheum."},{"key":"1441_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-026-03740-x","volume":"28","author":"DL Skerrett","year":"2026","unstructured":"Skerrett, D. L. et al. Effects of pentosan polysulfate sodium on synovial fluid biomarkers in moderate to severe knee osteoarthritis: an exploratory, phase 2, randomized, double-blind, placebo-controlled trial. Arthritis Res. Ther. 28, 73 (2026).","journal-title":"Arthritis Res. Ther."},{"key":"1441_CR110","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.curtheres.2005.12.012","volume":"66","author":"P Ghosh","year":"2005","unstructured":"Ghosh, P., Edelman, J., March, L. & Smith, M. Effects of pentosan polysulfate in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled pilot study. Curr. Ther. Res. Clin. Exp. 66, 552\u2013571 (2005).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"1441_CR111","volume":"75","author":"M Ahuja","year":"2023","unstructured":"Ahuja, M. et al. Therapeutic effects of pentosan polysulfate sodium on clinical and disease modifying outcomes in subjects with knee osteoarthritis [abstract]. Arthritis Rheumatol. 75, 1984 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR112","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.49938","volume":"9","author":"Y Zhang","year":"2026","unstructured":"Zhang, Y. et al. Infrapatellar fat pad glucocorticoid injection in knee osteoarthritis. JAMA Netw. Open 9, e2549938 (2026).","journal-title":"JAMA Netw. Open"},{"key":"1441_CR113","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1001\/jama.2025.3471","volume":"333","author":"F Pan","year":"2025","unstructured":"Pan, F. et al. Metformin for knee osteoarthritis in patients with overweight or obesity: a randomized clinical trial. JAMA 333, 1804\u20131812 (2025).","journal-title":"JAMA"},{"key":"1441_CR114","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neuroscience.2017.07.020","volume":"359","author":"MD Burton","year":"2017","unstructured":"Burton, M. D. et al. Pharmacological activation of AMPK inhibits incision-evoked mechanical hypersensitivity and the development of hyperalgesic priming in mice. Neuroscience 359, 119\u2013129 (2017).","journal-title":"Neuroscience"},{"key":"1441_CR115","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/annrheumdis-2019-216713","volume":"79","author":"J Li","year":"2020","unstructured":"Li, J. et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann. Rheum. Dis. 79, 635\u2013645 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152908","volume":"77","author":"C-L Kao","year":"2026","unstructured":"Kao, C.-L. et al. The efficacy of metformin for pain, function, and quality of life in knee osteoarthritis: a systematic review and meta-analysis. Semin. Arthritis Rheum. 77, 152908 (2026).","journal-title":"Semin. Arthritis Rheum."},{"key":"1441_CR117","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-026-08181-0","author":"Y Kang","year":"2026","unstructured":"Kang, Y. et al. Association of metformin with osteoarthritis progression and total joint arthroplasty: evidence from the UK Biobank, a large population-based cohort study. Clin. Rheumatol. https:\/\/doi.org\/10.1007\/s10067-026-08181-0 (2026).","journal-title":"Clin. Rheumatol."},{"key":"1441_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05323-7","volume":"12","author":"C Meurot","year":"2022","unstructured":"Meurot, C. et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci. Rep. 12, 1567 (2022).","journal-title":"Sci. Rep."},{"key":"1441_CR119","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/jor.26050","volume":"43","author":"A-S Scheike","year":"2025","unstructured":"Scheike, A.-S. et al. The anti-inflammatory effects of liraglutide in equine inflammatory joint models. J. Orthop. Res. 43, 893\u2013903 (2025).","journal-title":"J. Orthop. Res."},{"key":"1441_CR120","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2019.14735","volume":"322","author":"MC Hochberg","year":"2019","unstructured":"Hochberg, M. C. et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA 322, 1360\u20131370 (2019).","journal-title":"JAMA"},{"key":"1441_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10177-1","volume":"10","author":"S Mokuda","year":"2019","unstructured":"Mokuda, S. et al. Wwp2 maintains cartilage homeostasis through regulation of Adamts5. Nat. Commun. 10, 2429 (2019).","journal-title":"Nat. Commun."},{"key":"1441_CR122","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.joca.2021.08.012","volume":"30","author":"P Clement-Lacroix","year":"2022","unstructured":"Clement-Lacroix, P. et al. Pharmacological characterization of GLPG1972\/S201086, a potent and selective small-molecule inhibitor of ADAMTS5. Osteoarthr. Cartil. 30, 291\u2013301 (2022).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11610","author":"AR Bihlet","year":"2024","unstructured":"Bihlet, A. R. et al. Safety, tolerability, and pharmacodynamics of the ADAMTS-5 nanobody M6495: two phase 1, single-center, double-blind, randomized, placebo-controlled studies in healthy subjects and patients with osteoarthritis. ACR Open Rheumatol. https:\/\/doi.org\/10.1002\/acr2.11610 (2024).","journal-title":"ACR Open Rheumatol."},{"key":"1441_CR124","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1038\/s41591-022-02059-9","volume":"28","author":"N Gerwin","year":"2022","unstructured":"Gerwin, N. et al. Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial. Nat. Med. 28, 2633\u20132645 (2022).","journal-title":"Nat. Med."},{"key":"1441_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02622-8","volume":"23","author":"D McGuire","year":"2021","unstructured":"McGuire, D. et al. Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA. Arthritis Res. Ther. 23, 242 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"1441_CR126","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.joca.2025.11.010","volume":"34","author":"E-J Moon","year":"2026","unstructured":"Moon, E.-J. et al. E1K, a disease-modifying drug candidate for knee osteoarthritis, alleviates pain and regenerates cartilage simultaneously by inhibiting TGF-\u03b21-mediated SMAD1\/5\/9 signaling in osteoarthritis models. Osteoarthr. Cartil. 34, 240\u2013250 (2026).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR127","first-page":"S448","volume":"33","author":"S Kim","year":"2025","unstructured":"Kim, S. et al. E1K, a disease-modifying drug candidate for knee osteoarthritis: key findings on target population and optimal dosage from a post-hoc analysis of a phase 2 clinical trial [abstract 645]. Osteoarthr. Cartil. 33, S448 (2025).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR128","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse, R. & Clevers, H. Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985\u2013999 (2017).","journal-title":"Cell"},{"key":"1441_CR129","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nrrheum.2013.25","volume":"9","author":"RJ Lories","year":"2013","unstructured":"Lories, R. J., Corr, M. & Lane, N. E. To Wnt or not to Wnt: the bone and joint health dilemma. Nat. Rev. Rheumatol. 9, 328\u2013339 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR130","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/art.23614","volume":"58","author":"M Zhu","year":"2008","unstructured":"Zhu, M. et al. Inhibition of \u03b2-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum. 58, 2053\u20132064 (2008).","journal-title":"Arthritis Rheum."},{"key":"1441_CR131","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1359\/jbmr.080901","volume":"24","author":"M Zhu","year":"2009","unstructured":"Zhu, M. et al. Activation of \u03b2-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J. Bone Min. Res. 24, 12\u201321 (2009).","journal-title":"J. Bone Min. Res."},{"key":"1441_CR132","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/annrheumdis-2015-208577","volume":"76","author":"G Nalesso","year":"2017","unstructured":"Nalesso, G. et al. WNT16 antagonises excessive canonical WNT activation and protects cartilage in osteoarthritis. Ann. Rheum. Dis. 76, 218\u2013226 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR133","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.joca.2017.08.015","volume":"26","author":"V Deshmukh","year":"2018","unstructured":"Deshmukh, V. et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthr. Cartil. 26, 18\u201327 (2018).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR134","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/art.41315","volume":"72","author":"Y Yazici","year":"2020","unstructured":"Yazici, Y. et al. Lorecivivint, a novel intraarticular CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor and Wnt pathway modulator for the treatment of knee osteoarthritis: a phase ii randomized trial. Arthritis Rheumatol. 72, 1694\u20131706 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR135","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.joca.2021.02.004","volume":"29","author":"Y Yazici","year":"2021","unstructured":"Yazici, Y. et al. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2\/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthr. Cartil. 29, 654\u2013666 (2021).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR136","doi-asserted-by":"crossref","DOI":"10.1002\/art.42269","volume":"74","author":"Y Yazici","year":"2022","unstructured":"Yazici, Y. et al. A phase 2, 104-week study of repeat lorecivivint injections evaluating safety, efficacy, and bone health utilizing quantitative computed tomography (qCT) in knee osteoarthritis (OA-06) [abstract]. Arthritis Rheumatol. 74, 1894 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR137","first-page":"854","volume":"43","author":"Y Yazici","year":"2025","unstructured":"Yazici, Y. et al. A phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis. Clin. Exp. Rheumatol. 43, 854\u2013860 (2025).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1441_CR138","first-page":"847","volume":"43","author":"Y Yazici","year":"2025","unstructured":"Yazici, Y. et al. A phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients. Clin. Exp. Rheumatol. 43, 847\u2013853 (2025).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1441_CR139","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1093\/rheumatology\/keae610","volume":"64","author":"J Tambiah","year":"2025","unstructured":"Tambiah, J., Kennedy, S., Swearingen, C., McAlindon, T. & Yazici, Y. Impact of structural severity on outcomes in knee osteoarthritis: an analysis of data from phase 2 and phase 3 lorecivivint clinical trials. Rheumatology 64, 2583\u20132590 (2025).","journal-title":"Rheumatology"},{"key":"1441_CR140","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/0003-4819-134-7-200104030-00007","volume":"134","author":"DT Felson","year":"2001","unstructured":"Felson, D. T. et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann. Intern. Med. 134, 541\u2013549 (2001).","journal-title":"Ann. Intern. Med."},{"key":"1441_CR141","doi-asserted-by":"publisher","first-page":"330","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00008","volume":"139","author":"DT Felson","year":"2003","unstructured":"Felson, D. T. et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann. Intern. Med. 139, 330\u2013336 (2003).","journal-title":"Ann. Intern. Med."},{"key":"1441_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/ar3209","volume":"12","author":"D Dore","year":"2010","unstructured":"Dore, D. et al. Bone marrow lesions predict site-specific cartilage defect development and volume loss: a prospective study in older adults. Arthritis Res. Ther. 12, R222 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"1441_CR143","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41584-023-00971-z","volume":"19","author":"RT Hansen","year":"2023","unstructured":"Hansen, R. T., Chenu, C., Sofat, N. & Pitsillides, A. A. Bone marrow lesions: plugging the holes in our knowledge using animal models. Nat. Rev. Rheumatol. 19, 429\u2013445 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR144","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/keh411","volume":"44","author":"DT Felson","year":"2005","unstructured":"Felson, D. T. et al. Osteophytes and progression of knee osteoarthritis. Rheumatology 44, 100\u2013104 (2005).","journal-title":"Rheumatology"},{"key":"1441_CR145","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/art.37987","volume":"65","author":"T Neogi","year":"2013","unstructured":"Neogi, T. et al. Magnetic resonance imaging-based three-dimensional bone shape of the knee predicts onset of knee osteoarthritis: data from the Osteoarthritis Initiative. Arthritis Rheum. 65, 2048\u20132058 (2013).","journal-title":"Arthritis Rheum."},{"key":"1441_CR146","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/annrheumdis-2011-200970","volume":"71","author":"LL Laslett","year":"2012","unstructured":"Laslett, L. L. et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann. Rheum. Dis. 71, 1322\u20131328 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR147","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2020.2938","volume":"323","author":"G Cai","year":"2020","unstructured":"Cai, G. et al. Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: a randomized clinical trial. JAMA 323, 1456\u20131466 (2020).","journal-title":"JAMA"},{"key":"1441_CR148","doi-asserted-by":"publisher","first-page":"S593","DOI":"10.1016\/j.joca.2024.02.877","volume":"32","author":"WP Gielis","year":"2024","unstructured":"Gielis, W. P. et al. First clinical results of the ZODIAK trial: a randomized controlled trial comparing the therapeutic effect of zoledronic acid vs placebo in knee osteoarthritis [abstract 863]. Osteoarthr. Cartil. 32, S593\u2013S594 (2024).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR149","doi-asserted-by":"publisher","first-page":"12517","DOI":"10.1074\/jbc.271.21.12517","volume":"271","author":"MJ Bossard","year":"1996","unstructured":"Bossard, M. J. et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J. Biol. Chem. 271, 12517\u201312524 (1996).","journal-title":"J. Biol. Chem."},{"key":"1441_CR150","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.joca.2009.03.015","volume":"17","author":"JR Connor","year":"2009","unstructured":"Connor, J. R. et al. Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial medial meniscectomy model of osteoarthritis. Osteoarthr. Cartil. 17, 1236\u20131243 (2009).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR151","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.bone.2012.03.025","volume":"50","author":"T Hayami","year":"2012","unstructured":"Hayami, T., Zhuo, Y., Wesolowski, G. A., Pickarski, M. & Duong, L. T. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 50, 1250\u20131259 (2012).","journal-title":"Bone"},{"key":"1441_CR152","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.joca.2010.07.014","volume":"18","author":"JJ McDougall","year":"2010","unstructured":"McDougall, J. J., Schuelert, N. & Bowyer, J. Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis. Osteoarthr. Cartil. 18, 1355\u20131357 (2010).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR153","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41584-020-00533-7","volume":"17","author":"PR Coryell","year":"2021","unstructured":"Coryell, P. R., Diekman, B. O. & Loeser, R. F. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat. Rev. Rheumatol. 17, 47\u201357 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004440","volume":"21","author":"C Nguyen","year":"2024","unstructured":"Nguyen, C. et al. Oral resveratrol in adults with knee osteoarthritis: a randomized placebo-controlled trial (ARTHROL). PLoS Med. 21, e1004440 (2024).","journal-title":"PLoS Med."},{"key":"1441_CR155","doi-asserted-by":"publisher","first-page":"S479","DOI":"10.1016\/j.joca.2020.02.752","volume":"28","author":"B Hsu","year":"2020","unstructured":"Hsu, B. et al. Safety, tolerability, pharmacokinetics, and clinical outcomes following treatment of painful knee osteoarthritis with senolytic molecule UBX0101 [abstract 719]. Osteoarthr. Cartil. 28, S479\u2013S480 (2020).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR156","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.joca.2021.02.077","volume":"29","author":"N Lane","year":"2021","unstructured":"Lane, N. et al. A phase 2, randomized, double-blind, placebo-controlled study of senolytic molecule UBX0101 in the treatment of painful knee osteoarthritis [abstract 50]. Osteoarthr. Cartil. 29, S52\u2013S53 (2021).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR157","doi-asserted-by":"publisher","first-page":"S456","DOI":"10.1016\/j.joca.2025.02.667","volume":"33","author":"S Tashman","year":"2025","unstructured":"Tashman, S., Philippon, M., Dornan, G. & Huard, J. Results: from a randomized clinical trial evaluating the senolytic fisetin for treating knee osteoarthritis [abstract 659]. Osteoarthr. Cartil. 33, S456 (2025).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR158","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0332763","volume":"20","author":"N Siewe","year":"2025","unstructured":"Siewe, N. & Friedman, A. Modeling treatment of osteoarthritis with standard therapy and senolytic drugs. PLoS ONE 20, e0332763 (2025).","journal-title":"PLoS ONE"},{"key":"1441_CR159","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1001\/jama.2021.19415","volume":"326","author":"KL Bennell","year":"2021","unstructured":"Bennell, K. L. et al. Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: the RESTORE randomized clinical trial. JAMA 326, 2021\u20132030 (2021).","journal-title":"JAMA"},{"key":"1441_CR160","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/03635465241246524","volume":"53","author":"A Bensa","year":"2025","unstructured":"Bensa, A. et al. PRP injections for the treatment of knee osteoarthritis: the improvement is clinically significant and influenced by platelet concentration: a meta-analysis of randomized controlled trials. Am. J. Sports Med. 53, 745\u2013754 (2025).","journal-title":"Am. J. Sports Med."},{"key":"1441_CR161","doi-asserted-by":"publisher","DOI":"10.1177\/2325967120973284","volume":"9","author":"L-Y Nie","year":"2021","unstructured":"Nie, L.-Y., Zhao, K., Ruan, J. & Xue, J. Effectiveness of platelet-rich plasma in the treatment of knee osteoarthritis: a meta-analysis of randomized controlled clinical trials. Orthop. J. Sports Med. 9, 2325967120973284 (2021).","journal-title":"Orthop. J. Sports Med."},{"key":"1441_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2025.106014","volume":"93","author":"H Bard","year":"2025","unstructured":"Bard, H., Ornetti, P., No\u00ebl, \u00c9 & Eymard, F. Platelet-rich plasma and knee osteoarthritis: a critical overview of the multiple biases and methodological complexity. Jt. Bone Spine 93, 106014 (2025).","journal-title":"Jt. Bone Spine"},{"key":"1441_CR163","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/0363546517732734","volume":"46","author":"E Kon","year":"2018","unstructured":"Kon, E., Engebretsen, L., Verdonk, P., Nehrer, S. & Filardo, G. Clinical outcomes of knee osteoarthritis treated with an autologous protein solution injection: a 1-year pilot double-blinded randomized controlled trial. Am. J. Sports Med. 46, 171\u2013180 (2018).","journal-title":"Am. J. Sports Med."},{"key":"1441_CR164","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3390\/jcm10132925","volume":"10","author":"M Sanchez-Diaz","year":"2021","unstructured":"Sanchez-Diaz, M. et al. Biodistribution of mesenchymal stromal cells after administration in animal models and humans: a systematic review. J. Clin. Med. 10, 2925 (2021).","journal-title":"J. Clin. Med."},{"key":"1441_CR165","volume":"4","author":"SL Whittle","year":"2025","unstructured":"Whittle, S. L. et al. Stem cell injections for osteoarthritis of the knee. Cochrane Database Syst. Rev. 4, CD013342 (2025).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1441_CR166","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.ard.2025.07.026","volume":"84","author":"Y-M Pers","year":"2025","unstructured":"Pers, Y.-M. et al. Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial. Ann. Rheum. Dis. 84, 2103\u20132114 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1441_CR167","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1038\/s41591-023-02632-w","volume":"29","author":"K Mautner","year":"2023","unstructured":"Mautner, K. et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat. Med. 29, 3120\u20133126 (2023).","journal-title":"Nat. Med."},{"key":"1441_CR168","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/bjsports-2024-108732","volume":"59","author":"KW Barfod","year":"2025","unstructured":"Barfod, K. W. et al. Treatment of knee osteoarthritis with a single injection of autologous micro-fragmented adipose tissue is not superior to a placebo saline injection: a blinded randomised controlled trial with 2-year follow-up. Br. J. Sports Med. 59, 1219\u20131227 (2025).","journal-title":"Br. J. Sports Med."},{"key":"1441_CR169","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41584-023-01067-4","volume":"20","author":"CR DeJulius","year":"2024","unstructured":"DeJulius, C. R. et al. Engineering approaches for RNA-based and cell-based osteoarthritis therapies. Nat. Rev. Rheumatol. 20, 81\u2013100 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR170","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/humc.2017.249","volume":"29","author":"M-K Kim","year":"2018","unstructured":"Kim, M.-K. et al. A multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients. Hum. Gene Ther. Clin. Dev. 29, 48\u201359 (2018).","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"1441_CR171","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/s-0038-1676803","volume":"33","author":"B Lee","year":"2020","unstructured":"Lee, B. et al. Results of a phase II study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-\u03b21. J. Knee Surg. 33, 167\u2013172 (2020).","journal-title":"J. Knee Surg."},{"key":"1441_CR172","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.joca.2021.05.023","volume":"29","author":"E Grigsby","year":"2021","unstructured":"Grigsby, E. et al. XT-150- A novel immunomodulatory gene therapy for osteoarthritis pain in phase 2b development [abstract LBA-17]. Osteoarthr. Cartil. 29, S12 (2021).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR173","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.joca.2024.02.061","volume":"32","author":"H Rutman","year":"2024","unstructured":"Rutman, H. et al. Efficacy of XT-150, a novel non-viral gene therapy delivering IL-10v, on moderate to severe pain due to knee osteoarthritis: patient subgroup analysis [abstract 050]. Osteoarthr. Cartil. 32, S41 (2024).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR174","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/hum.2021.131","volume":"33","author":"R Senter","year":"2022","unstructured":"Senter, R. et al. Efficacy and safety of FX201, a novel intra-articular IL-1Ra gene therapy for osteoarthritis treatment, in a rat model. Hum. Gene Ther. 33, 541\u2013549 (2022).","journal-title":"Hum. Gene Ther."},{"key":"1441_CR175","volume":"77","author":"S Cohen","year":"2025","unstructured":"Cohen, S. et al. PCRX-201 high-capacity adenovirus serotype 5 gene therapy demonstrates sustained clinical efficacy and safety in patients with knee osteoarthritis [abstract]. Arthritis Rheumatol. 77, 2103 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1441_CR176","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.joca.2026.01.061","volume":"34","author":"J Tambiah","year":"2026","unstructured":"Tambiah, J. et al. Intra-articular gene therapy GNSC-001 for knee osteoarthritis: 12-month results: from a phase 1b trial (DONATELLO) with safety, pharmacodynamics and exploratory patient reported outcomes [abstract 049]. Osteoarthr. Cartil. 34, S63 (2026).","journal-title":"Osteoarthr. Cartil."},{"key":"1441_CR177","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41584-024-01126-4","volume":"20","author":"A Mobasheri","year":"2024","unstructured":"Mobasheri, A. & Loeser, R. Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development. Nat. Rev. Rheumatol. 20, 525\u2013526 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1441_CR178","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03563-2","volume":"27","author":"Y Liu","year":"2025","unstructured":"Liu, Y., Molchanov, V., Brass, D. & Yang, T. Recent advances in omics and the integration of multi-omics in osteoarthritis research. Arthritis Res. Ther. 27, 100 (2025).","journal-title":"Arthritis Res. Ther."},{"key":"1441_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101852","volume":"37","author":"A Mobasheri","year":"2023","unstructured":"Mobasheri, A. et al. Biomarkers for osteoarthritis: current status and future prospects. Best. Pract. Res. Clin. Rheumatol. 37, 101852 (2023).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1441_CR180","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41584-021-00719-7","volume":"18","author":"F Caliv\u00e0","year":"2022","unstructured":"Caliv\u00e0, F. et al. Studying osteoarthritis with artificial intelligence applied to magnetic resonance imaging. Nat. Rev. Rheumatol. 18, 112\u2013121 (2022).","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01441-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01441-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01441-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:29Z","timestamp":1792022849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01441-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":180,"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01441-y","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"9 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C. reports consulting fees and\/or advisory board participation from UCB, AbbVie, Novartis, Pfizer, Bristol Myers Squibb, IBSA and Janssen; has received support for attending scientific meetings from Pfizer, Roche, AbbVie, UCB, Bristol Myers Squibb, Novartis, Janssen and Biogen. T.W. is co-founder and co-chair of the Advanced Therapies in Orthopaedics Foundation \u2014 AtiO; provides scientific consulting on the advisory boards of Relive, Enlivex, Liposphere, Sunac, Heraeus Medical and Pluri Biotech. P.G.C. has acted as a consultant and speaker for AbbVie, AstraZeneca, Biosplice, Eli Lilly, Enlivex, Formation Bio, Genascence, Grunenthal, Kolon TissueGene, Levicept, Moebius, Novartis, Pacira and Sanofi & Stryker. F.B. reports consulting fees from Grunenthal, GSK, Eli Lilly, Novartis, Pfizer, Servier and 4P Pharma; reports honoraria from Viatris, Pfizer, and Zoetis; travel support from Nordic Pharma; holds patents related to 4Moving Biotech; serves on advisory boards for AstraZeneca, Sun Pharma and Nordic Bioscience; holds stock in 4P Pharma and 4Moving Biotech CMO; and is a co-founder of 4Moving Biotech, which is developing an intra-articular GLP1 agonist.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}